English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that an artificial intelligence-based analysis model enables accurate detection of definite radiographic sacroiliitis in people with axial spondyloarthritis, an advance that could be useful for both diagnosis in the clinic and classification of patients for inclusion in clinical trials.
Tag: ACR Convergence
Romosozumab Substantially Builds Bone Density in Hip and Spine, With Even More Gains When Followed by Antiresorptive Drug
New research presented at ACR Convergence, the American College Rheumatology’s annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.
Patients Reported International Hydroxychloroquine Shortages Due to COVID-19
A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment. Patients who could not access their antimalarial drugs faced worse physical and mental health outcomes as a result. Details of the research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Black Patients with Lupus Have Three Times Higher Risk of Stroke, 24 Times Higher Risk of Ischemic Heart Disease
New research reveals that, in the U.S., Black patients with lupus have a threefold higher risk of stroke and a 24-fold higher risk of ischemic heart disease. The study also found several lupus-specific symptoms that predict stroke and IHD in these patients. Details of the study was presented at ACR Convergence, the American College Rheumatology’s annual meeting.
Therapeutic Drug Monitoring Does Not Improve Remission for Patients Starting Infliximab
New research presented at ACR Convergence, the American College Rheumatology’s annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.
Key Features of Chronic Nonbacterial Osteomyelitis, a Disease Affecting Children and Young Adults, Identified in Groundbreaking Study
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, identified key clinical features of chronic nonbacterial osteomyelitis (CNO), which leads to an important step toward the development of much-needed classification criteria for a disease that affects children and young adults worldwide.
COVID-19 Infection Rates Low in People with Rheumatic Diseases, Most Report Mild Illness
A new study shows that the COVID-19 infection incidence has been low in people with rheumatic diseases, and most of those infected experience a mild course of illness. Additionally, fatalities have been low among rheumatic disease patients infected with COVID-19. Details of this research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Tuberculosis Screening Needed for Methotrexate Users in At-Risk Locales
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that tuberculosis (TB) screening and ongoing clinical care is needed for people on methotrexate who live in areas where the highly infectious illness is common. Methotrexate users who also take corticosteroids or other immunosuppressant therapies are at particular risk and need adequate TB screening.
With Close Monitoring Throughout, Safe Pregnancy is Possible for Women with Interstitial Lung Disease
A new study shows that women with interstitial lung disease (ILD) related to autoimmune disease may not need to terminate their pregnancies provided they have close monitoring from their team of multidisciplinary physicians before, during and after pregnancy. Results of the research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Global Survey Reveals that Few Children with Rheumatic Disease Report Contracting COVID-19, None Hospitalized
Results from a large, international survey shows that only a small fraction of children with rheumatic diseases reported contracting COVID-19. Those who did become infected, all had benign outcomes and did not develop significant complications, despite the fact that most children were taking immunosuppressive medications. The research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Hydroxychloroquine Has No Significant Impact on Heart Rhythm in Lupus Patients, Even Those with Chronic Kidney Disease
New research shows that adults with lupus who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals even if they have chronic kidney disease. The study was presented at ACR Convergence, the American College Rheumatology’s annual meeting.
New Juvenile Idiopathic Arthritis Guideline Emphasizes Disease-Modifying Treatments, Urges Immunizations
The American College of Rheumatology (ACR) will preview a new clinical practice guideline for the management of juvenile idiopathic arthritis (JIA) at ACR Convergence, the ACR’s annual meeting. The new recommendations include treatments for systemic JIA, oligoarthritis, TMJ arthritis, and recommendations for medication monitoring and immunizations.
Children with Kawasaki Disease at Higher Risk for Heart Problems More Than 10 Years After They Leave the Hospital
New research shows that children with Kawasaki Disease remain at an increased risk for cardiovascular events more than 10 years after hospitalization for their condition, highlighting the need for long-term heart disease surveillance and risk reduction strategies for these young patients. Details of the study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Black Patients with RA Less Likely to Receive a Biologic, More Likely to Be Treated with Glucocorticoids Than Whites
A new study reveals that Black patients with rheumatoid arthritis were less likely to be prescribed a biologic treatment and more likely to use glucocorticoids, which carry a risk of serious long-term side effects. This study highlights ongoing racial disparities in the care of patients with rheumatic disease. Details of the study was shared at ACR Convergence, the American College of Rheumatology’s annual meeting.
Osteoporosis Is Underdiagnosed and Undertreated in Older Men
A new study reveals that many older men who experience a fracture are still underdiagnosed with and undertreated for osteoporosis. Details of the study was presented at ACR Convergence, the American College Rheumatology’s annual meeting.
Warfarin Use Significantly Increases Risk of Knee and Hip Replacement in People with OA
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that use of warfarin, a vitamin K drug widely prescribed to prevent blood clots, is associated with a significantly greater risk of knee and hip replacements in patients with osteoarthritis.
Oral Methotrexate Significantly Improves Function in People with Primary Knee OA with Inflammation After Only Three Months
A new study presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that after three months of treatment with oral methotrexate, adults with primary knee osteoarthritis (OA) had significant improvements in physical function and inflammation, a sign that this inexpensive, generic pill may be an important intervention for knee OA.
Many with Lupus at High Risk for Adverse Reactions to Pneumocystis Pneumonia Preventive Drug
New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX) are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies. Details of the study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Steroid Injections Do Not Hasten the Need for Knee Replacement When Compared to Hyaluronic Acid Treatments for Adults with Knee OA
New research shows that corticosteroid injections for knee OA treatment do not hasten a patient’s progression to a total knee replacement when compared with hyaluronic acid injections. Details of this study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
Hydroxychloroquine Not Linked to Longer Heart Rhythm Intervals in Rheumatoid Arthritis or Lupus Patients
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, discovers that use of hydroxychloroquine does not cause any significant differences in QTc length or prolonged QTc in people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).
Telemedicine Reduces Cancellations and No-Shows for Rheumatology Care During COVID in Large Ohio Health System
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that expanded use of telemedicine during COVID-19 improved cancellation rates, no-shows and completed medical visits for rheumatology ambulatory clinics in one large Ohio health system.
New Rheumatoid Arthritis Guideline Emphasizes Maximizing Methotrexate and Biologics, Minimizing Steroids
The American College of Rheumatology (ACR) will preview its 2020 Guideline for the Management of Rheumatoid Arthritis (RA) at ACR Convergence, the ACR’s annual meeting. The comprehensive, clinical recommendations for pharmacologic treatment of RA includes important updates to the previous guideline released in 2015.
Minority Patients with Rheumatic Diseases Have Worse COVID-19 Outcomes, More Likely to Be Hospitalized
New research at ACR Convergence, the American College of Rheumatology’s annual meeting, reveals that people of color with rheumatic disease have worse health outcomes from COVID-19 infection, are more likely to be hospitalized to treat their coronavirus infection, and are more likely to require invasive ventilator treatment.